Efficacy of Quetiapine XR vs. Placebo as Concomitant Treatment to Mood Stabilizers in the Control of Subsyndromal Symptoms of Bipolar Disorder.

Trial Profile

Efficacy of Quetiapine XR vs. Placebo as Concomitant Treatment to Mood Stabilizers in the Control of Subsyndromal Symptoms of Bipolar Disorder.

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Sep 2017

At a glance

  • Drugs Quetiapine (Primary)
  • Indications Bipolar I disorders; Bipolar II disorders
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Sep 2017 Primary endpoint has been met. (Differences between the study drug and placebo in the change from baseline to week 6 on the Montgomery-sberg Depression Rating Scale (MADRS)) as per results published in the European Neuropsychopharmacology
    • 04 Sep 2017 Results published in the European Neuropsychopharmacology
    • 01 Jul 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top